BofA/Merrill Lynch initiates coverage on Ardea Biosciences (Nasdaq: RDEA) (PT $24) and Repligen (Nasdaq: REGN) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE